U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma
PhysIQ and U.S. Veteran’s Affairs Advance to Interventional Trial Phase
In The Know: Healthcare News for February 8, 2021
Medtech Innovation & Adaptation: Insights with Boston Scientific’s David Knapp